+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Mannkind Corporation - logo

MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

From
From
Global Type 1 Diabetes Drugs Market 2021-2025 - Product Thumbnail Image

Global Type 1 Diabetes Drugs Market 2021-2025

  • Report
  • May 2021
  • 120 Pages
From
Anaphylaxis (Immunology) - Drugs in Development, 2021 - Product Thumbnail Image

Anaphylaxis (Immunology) - Drugs in Development, 2021

  • Drug Pipelines
  • September 2021
  • 67 Pages
From
Diabetes Drug Delivery Devices Market, 2020-2030 - Product Thumbnail Image

Diabetes Drug Delivery Devices Market, 2020-2030

  • Report
  • August 2020
  • 147 Pages
From
Global Diabetes Market 2022-2028 - Product Thumbnail Image

Global Diabetes Market 2022-2028

  • Report
  • April 2022
  • 150 Pages
From
From
From
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2020 - Product Thumbnail Image

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 733 Pages
From
From
Loading Indicator